PSMC2 promotes hepatocellular carcinoma progression through interaction with EGFR
Open Access
- 24 May 2026
- journal article
- research article
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 26 (1)
Abstract
Growing evidence highlights the critical involvement of the ubiquitin-proteasome system in cancer development. As an essential component of the 26 S proteasome, Proteasome 26 S Subunit ATPase 2 (PSMC2) has been implicated in various malignancies, but its role in hepatocellular carcinoma (HCC) progression remains poorly understood. We analyzed PSMC2 expression using The Cancer Genome Atlas database (TCGA) database, and validated findings in clinical HCC specimens and cell lines through immunohistochemistry (IHC) and Western blot. Functional assays (CCK-8, colony formation, Scratch test and transwell invasion assay) were performed to assess the oncogenic properties of PSMC2 in the progression of HCC. Mechanistic studies employed co-immunoprecipitation, Western blot, immunofluorescence and in vivo xenograft models to investigate PSMC2-EGFR interactions and downstream signaling. PSMC2 was significantly overexpressed in HCC tissues and correlated with poor patient prognosis. Genetic knockdown of PSMC2 inhibited HCC cell proliferation, migration, and invasion in vitro, while suppressing tumor growth in vivo. Conversely, PSMC2 overexpression enhanced malignant phenotypes. Mechanistically, PSMC2 physically interacted with EGFR, stabilizing EGFR protein levels and enhancing phosphorylation of downstream AKT and ERK1/2 pathways. Our study identifies PSMC2 as a novel regulator of HCC progression through EGFR-AKT/ERK1/2 signaling axis activation. These findings position PSMC2 as both a prognostic biomarker and a potential therapeutic target for HCC intervention.Keywords
Funding Information
- Talent research project of Suzhou Gusu Health Talents Program (GSWS202037)
- National Natural Science Foundation of China (82102826)
- State Key Laboratory of Radiation Medicine and Protection (GZK12024032)
This publication has 40 references indexed in Scilit:
- PSMC2 promotes resistance against temozolomide in glioblastoma via suppressing JNK-mediated autophagic cell deathBiochemical Pharmacology, 2025
- A MYC-STAMBPL1-TOE1 positive feedback loop mediates EGFR stability in hepatocellular carcinomaCell Reports, 2024
- Genomic Amplification of TBC1D31 Promotes Hepatocellular Carcinoma Through Reducing the Rab22A‐Mediated Endolysosomal Trafficking and Degradation of EGFRAdvanced Science, 2024
- PSMC2 promotes glioma progression by regulating immune microenvironment and PI3K/AKT/mTOR pathwayImmunobiology, 2024
- The Absence of Intra‐Tumoral Tertiary Lymphoid Structures is Associated with a Worse Prognosis and mTOR Signaling Activation in Hepatocellular Carcinoma with Liver Transplantation: A Multicenter Retrospective StudyAdvanced Science, 2024
- SP1‐activated USP27X‐AS1 promotes hepatocellular carcinoma progression via USP7‐mediated AKT stabilisationClinical and Translational Medicine, 2024
- Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistanceDrug Resistance Updates, 2020
- Evaluating the landscape of gene cooperativity with receptor tyrosine kinases in liver tumorigenesis using transposon-mediated mutagenesisJournal of Hepatology, 2019
- Cancer Vulnerabilities Unveiled by Genomic LossCell, 2012
- ATP Binds to Proteasomal ATPases in Pairs with Distinct Functional Effects, Implying an Ordered Reaction CycleCell, 2011